Diverse Effects of the Lingzhi or Reishi Medicinal Mushroom, Ganoderma lucidum (Agaricomycetes), in Combination with Tamoxifen Citrate and Doxorubicin in MCF-7 Breast Cancer Cells

Basit Öğe Kaydı
dc.contributor.authorAtay, Sevcan
dc.contributor.authorAk, Handan
dc.contributor.authorKalmis, Erbil
dc.contributor.authorKayalar, Husniye
dc.contributor.authorAydin, Hikmet Hakan
dc.date.accessioned2019-10-27T22:57:49Z
dc.date.available2019-10-27T22:57:49Z
dc.date.issued2016
dc.departmentEge Üniversitesien_US
dc.description.abstractGanoderma lucidum, a medicinal mushroom, has been known to have antimetastatic and anti-carcinogenic bioactivities and is widely used in Asian countries in complementary and alternative medicine. However, there is no information regarding its combined usage with tamoxifen and doxorubicin in breast cancer treatment. We investigated the interactions between G. lucidum and tamoxifen or doxorubicin in an MCF-7 human estrogen receptor-positive breast cancer cell line. The antiproliferative properties of 6 extracts were assessed using the WST-8 method. The most effective extract in inhibiting MCF-7 cell viability was then evaluated in terms of its antimetastatic activity by the Boyden chamber assay. Apoptosis and cell cycle assays were performed by flow cytometry. G. lucidum ether extract (G. Ether) was the most effective extract in inhibiting cell viability, among other extracts, with half-maximal inhibitory concentrations of 100 and 12.82 mu g/mL at 48 and 72 hours, respectively. We found that G. Ether is capable of inducing apoptosis and changing cell cycle dynamics. However, incubation with G. Ether did not significantly affect MCF-7 cell motility. We then assessed the interactions between G. Ether and tamoxifen or doxorubicin in MCF-7 cells. The interactions between G. Ether and cancer therapeutics were examined by combination index analysis and MacSynergy II software. Interestingly, G. Ether increased the antiproliferative effect of tamoxifen but exhibited strong antagonism with doxorubicin in the MCF-7 cell line.en_US
dc.identifier.doi10.1615/IntJMedMushrooms.v18.i6.30
dc.identifier.endpage499en_US
dc.identifier.issn1521-9437
dc.identifier.issn1940-4344
dc.identifier.issn1521-9437en_US
dc.identifier.issn1940-4344en_US
dc.identifier.issue6en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage489en_US
dc.identifier.urihttps://doi.org/10.1615/IntJMedMushrooms.v18.i6.30
dc.identifier.urihttps://hdl.handle.net/11454/51343
dc.identifier.volume18en_US
dc.identifier.wosWOS:000386997500003en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherBegell House Incen_US
dc.relation.ispartofInternational Journal of Medicinal Mushroomsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectbreast canceren_US
dc.subjectdoxorubicinen_US
dc.subjectGanoderma lucidumen_US
dc.subjectMCF-7en_US
dc.subjectmedicinal mushroomsen_US
dc.subjecttamoxifenen_US
dc.titleDiverse Effects of the Lingzhi or Reishi Medicinal Mushroom, Ganoderma lucidum (Agaricomycetes), in Combination with Tamoxifen Citrate and Doxorubicin in MCF-7 Breast Cancer Cellsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu